A Spotlight on the TGF-β Cancer Clinical Trial Landscape

The multibillion-dollar pursuit to unlock the double-edged sword of TGF-β immuno-oncology therapeutics is firmly underway. The perfect mix of continued investment, increasing evidence and the promise of preclinical and clinical success has seen this space gather momentum again after recent clinical setbacks.

The formidable TGF-β race for approval remains as dynamic and thrilling as ever; combinational therapeutics including small molecule therapies, antibodies, cell therapies and more are in preclinical and clinical development to bring novel, gold-standard, cancer immunotherapies to the market, and patients in need.